Email this article Cerebrovascular complications in metabolic syndrome: possible approaches to a lower risk
- Authors: Chazova IE1, Mychka VВ1, Mamyrbaeva КМ1, Gornostaev VV1, Dvoskina IM1, Sergienko VB1
-
Affiliations:
- Issue: Vol 79, No 6 (2004)
- Pages: 74-80
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29855
- ID: 29855
Cite item
Full Text
Abstract
Aim. To compare brain perfusion in hypertensive patients with diabetes mellitus type 2 (DM2) or metabolic (MS) syndrome and hypertensive patients without clinicobiochemical signs of DM2 or MS; to study enoxapahn effects on brain perfusion in DM2 and arterial hypertension (AH). Material and methods. Seventy patients included in the study were divided into three groups: 30 patients with DM2 and AH (group 1), 30 patients with MS and AH (group 2)and 10 AH patients without manifestations of MS or DM2 (group 3). All the patients have undergone single-photon emission computed tomography (SPECT) of the brain, carbohydrate and lipid metabolism were examined. Results. Deterioration of brain perfusion was more prominent in DM2 and MS patients with AH than in hypertensive patients with normal metabolism. Stress test with acetasolamide revealed defective autoregulation of cerebral blood flow in hypertensive patients with DM2. A 6-week therapy with enoxapahn significantly improved brain perfusion in hypehensive patients with DM2. Conclusion. Enoxapahn treatment of hypehensive DM2 and MS patients with abnormal perfusion of the brain can be used for prevention of cerebrovascular complications.
References
- Смертность населения Российской Федерации. 2000 г.: Статистические материалы. М.: Минздрав РФ; 2001.
- Верещагин Н. В., Моргунов В. А., Гулевская Т. С. Патология головного мозга при атеросклерозе и артериальной гипертонии. М.: Медицина; 1997.
- Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18 (2): 258-268.
- Kannel W. В., McGee D. L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2: 120-126.
- Ruitenberg A., Skoog J., Ott A. et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg. H-70 Study. Dement. Geriatr. Cegh. Disord. 2001; 12 (1): 33-39.
- Counsell C., Sandercock P. Anticoagulant therapy compared to control in patients with acute presumed ischemic stroke (Cochrane review). Cochrane Library 1998; N 2.
- Гогин Е. Е., Шмырев В. И. Цереброваскулярные осложнения гипертонической болезни: дисциркуляторная энцефалопатия, инсульты. Тер. арх. 1997; 4: 5-10.
- Stamler J., Vaccaro О., Neaton J. D. et al. Diabetes, other risk factors and 12 years cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
- Juhan-Vague I., Thompson S. G., Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler. Thromb. 1993; 13: 1865-1873.
- Weigh D. S. Leptin and other secretory products of adypocytes modulate multiple physiological functions. Ann. Endocrinol. 1997; 58: 132-136.
- Castelli W. P. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am. Heart J. 1983; 106: 1191-1200.
- Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reduction in blood pressure: overview of randomized drag trials in their epidemiological context. Lancet 1990; 335: 827-838.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
- Шалънова С. А., Деев А. Д., Оганов Р. Г. Распространенность, информированность, лечение и контроль артериальной гипертонии среди населения России. В кн.: Материалы Первой Всероссийской конф. по проблемам атеросклероза. М.; 1999. 165.
Supplementary files
